BioSpace News Archive

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company is eliminating approximately 15 positions through a reduction in headcount across the organization.

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “The Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company supported the launch of the Alliance for Advancing Bioelectronic Medicine (AABM), an independent network of professionals united to support bioelectronic medicine.

SaVida Health, a leader in medication-assisted treatment for opioid and alcohol addiction, is opening a new outpatient treatment center in Abingdon, Virginia on November 18.

FDA Pulmonary, Allergy, and Rheumatology Division Veteran and Researcher Will Oversee the Company’s Medical and Regulatory Strategy

Medicare Advantage and Commercial formularies to include EUFLEXXA, hyaluronic sodium, as a co-preferred HA for osteoarthritis knee pain

Sensei Biotherapeutics, Inc. announced the dosing of the first patient in its Phase 1/2 clinical trial evaluating SNS-301 in patients with ASPH‑positive head and neck cancer who have previously received immune checkpoint inhibitors.

Vifor Pharma announced the appointment of Lee Heeson as President International and member of the Executive Committee as of February 1st, 2020.

Freudenberg Medical, a global developer and manufacturer of medical devices, components, and minimally invasive solutions, has launched a major innovation initiative - backed by a multimillion-dollar annual investment in R&D - over all its business entities.

InDex Pharmaceuticals Holding AB announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19.

ITM Isotopen Technologien München AG and Chengdu Gaotong Isotope Co., Ltd. announced that they have signed a technology license agreement for the production and distribution of ITM Germanium-68/Gallium-68 Generators and no-carrier-added Lutetium-177 in China.